| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454698 | Lung Cancer | 2016 | 4 Pages |
Abstract
Nivolumab might have intracranial activity and favorable safety profile in patients with CNS metastases secondary to NSCLC. Nivolumab CNS activity warrants further evaluation.
Keywords
FDAPD-1PD-L1LeptomeningealmRECISTWBRTSRSPTSNivolumabK-RasPET-CTMRIPatientsMagnetic resonance imagingCNSStereotactic radiosurgeryNSCLCNon-small cell lung cancercentral nervous systemprogrammed cell death ligand-1Brain metastasesmodified Response Evaluation Criteria in Solid TumorsWhole brain radiation therapyprogrammed cell death protein-1Kirsten Rat Sarcoma
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Elizabeth Dudnik, Shlomit Yust-Katz, Hovav Nechushtan, Daniel A. Goldstein, Alona Zer, Dov Flex, Tali Siegal, Nir Peled,